According to a tweet by theStreet.com's Adam Feurstein, a Bloomberg reporter said that Clinical Data CLDA will either be acquired or market vilazodone on its own.
CLDA shares have pulled back sharply in the last few minutes, but are still up 2.31% on the session at $31.07.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in